Publicaciones en colaboración con investigadores/as de Università di Perugia (60)

2024

  1. Negative symptoms and sex differences in first episode schizophrenia: What's their role in the functional outcome? A longitudinal study

    Spanish Journal of Psychiatry and Mental Health

2023

  1. Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive

    Internal and Emergency Medicine, Vol. 18, Núm. 6, pp. 1619-1634

  2. Bleeding risk with concomitant administration of VEGF-TKIs and anticoagulant agents

    Seminars in Oncology, Vol. 50, Núm. 3-5, pp. 67-70

  3. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies

    Rheumatology (United Kingdom), Vol. 62, Núm. 1, pp. 243-255

  4. Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology

    Allergy: European Journal of Allergy and Clinical Immunology

  5. Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism

    European Journal of Internal Medicine, Vol. 112, pp. 29-36

  6. The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

    American Journal of Hematology, Vol. 98, Núm. 12, pp. 1856-1868

2022

  1. Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer

    Thrombosis and Haemostasis, Vol. 122, Núm. 5, pp. 796-807

  2. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain

    Journal of Medical Economics, Vol. 25, Núm. 1, pp. 840-847

  3. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

    Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

  4. Percutaneous transaxillary access for endovascular aortic procedures in the multicenter international PAXA registry

    Journal of Vascular Surgery, Vol. 75, Núm. 3, pp. 868-876.e3

  5. Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study

    European Journal of Cancer, Vol. 165, pp. 136-145

  6. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

    The Lancet, Vol. 399, Núm. 10333, pp. 1383-1390

  7. Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe

    Neuropsychiatric Disease and Treatment, Vol. 18, pp. 201-219

  8. Venous thromboembolism risk, prophylaxis and management in cancer patients with COVID-19: An unmet medical need

    Thrombosis Update, Vol. 6

2021

  1. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

    Leukemia, Vol. 35, Núm. 12, pp. 3444-3454

  2. Corrigendum to "Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 32 (2021) 439-451

    Annals of oncology : official journal of the European Society for Medical Oncology

  3. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism

    European Journal of Cancer, Vol. 148, pp. 371-381

  4. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  5. Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 90-113